Dr. Rao on dual PARP/AR inhibition in mCRPC


Arpit Rao, MD, an associate professor of Medical Oncology at Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the benefit of dual inhibition of the PARP and androgen receptor (AR) pathways in patients with prostate cancer. He also explains that a successful phase 2 trial (doi: 10.1016/S1470-2045(18)30365-6) of the AR pathway inhibitor (ARPI) abiraterone acetate (Zytiga) combined with the PARP inhibitor olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer (mCRPC) inspired his colleagues and him to launch the CASPAR (Alliance A031902) trial, a randomized phase 3 trial of the ARPI enzalutamide (Xtandi) combined with the PARP inhibitor rucaparib (Rubraca) in patients with mCRPC (NCT04455750).

Related Videos
Veda Giri, MD, answers a question during a Zoom video interview
Genetic testing for prostate cancer | Image credit: © ktsdesign - stock.adobe.com
DNA molecules
DNA strand illustration
illustration of double helix
illustration of DNA molecule
Related Content
© 2023 MJH Life Sciences

All rights reserved.